What is claimed is:

1. An immunotherapeutic composition comprising:

a) a yeast vehicle; and

b) a fusion protein comprising HBV antigens, wherein the HBV antigens consist of:

i) an HBV X antigen having an amino acid sequence that is at least 80% identical to positions 52 to 126 of a full-length HBV X antigen;

ii) an HBV surface antigen having an amino acid sequence that is at least 95% identical to an amino acid sequence of a full-length HBV large surface antigen (L), and;

iii) an HBV core antigen having an amino acid sequence that is at least 95% identical to an amino acid sequence of a full-length HBV core protein;

wherein the composition elicits an HBV-specific immune response.

2. The immunotherapeutic composition of Claim 1, wherein the amino acid sequence of HBV X antigen is at least 95% identical to an amino acid sequence selected from: positions 1-60 of SEQ ID NO:130, positions 630-689 of SEQ ID NO:110, positions 582-641 of SEQ ID NO:122, positions 630-689 of SEQ ID NO:107, positions 630-689 of SEQ ID NO:108, positions 630-689 of SEQ ID NO:109, positions 52-68 followed by positions 84-126 of SEQ ID NO:4, positions 52-68 followed by positions 84-126 of SEQ ID NO:8, positions 52-68 followed by positions 84-126 of SEQ ID NO:12, positions 52-68 followed by positions 84-126 of SEQ ID NO:16, positions 52-68 followed by positions 84-126 of SEQ ID NO:20, positions 52-68 followed by positions 84-126 of SEQ ID NO:24, positions 52-68 followed by positions 84-126 of SEQ ID NO:28, positions 52-68 followed by positions 84-126 of SEQ ID NO:32, SEQ ID NO:100, positions 719-778 of SEQ ID NO:101, positions 635-694 of SEQ ID NO:102, positions 810-869 of SEQ ID NO:124, positions 582-641 of SEQ ID NO:126, positions 229 to 288 of SEQ ID NO:132, positions 1 to 60 of SEQ ID NO:134, or a corresponding sequence from a different HBV strain.

3. The immunotherapeutic composition of Claim 1, wherein the amino acid sequence of HBV X antigen is selected from: positions 1-60 of SEQ ID NO:130, positions 630-689 of SEQ ID NO:110, positions 582-641 of SEQ ID NO:122, positions 630-689 of SEQ ID NO:109, positions 630-689 of SEQ ID NO:108, positions 630-689 of

SEQ ID NO:107, SEQ ID NO:100, or a corresponding sequence from a different HBV strain.

4. The immunotherapeutic composition of any one of Claims 1 to 3, wherein the amino acid sequence of the HBV surface antigen is at least 95% identical to an amino acid sequence selected from: positions 63-461 of SEQ ID NO:130, positions 1-399 of SEQ ID NO:118, positions 1-399 of SEQ ID NO:122, positions 9-407 of SEQ ID NO:34, positions 1-399 of SEQ ID NO:112, positions 1-399 of SEQ ID NO:114, positions 1-399 of SEQ ID NO:116, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:19, SEQ ID NO:23, SEQ ID NO:27, SEQ ID NO:31, positions 90-488 of SEQ ID NO:93, positions 1-399 of SEQ ID NO:120, positions 1-399 of SEQ ID NO:124, positions 1-399 of SEQ ID NO:126, positions 231-629 of SEQ ID NO:128, positions 289-687 of SEQ ID NO:132, positions 289-687 of SEQ ID NO:134, or a corresponding sequence from a different HBV strain.

5. The immunotherapeutic composition of any one of Claims 1 to 4, wherein the amino acid sequence of the HBV surface antigen is selected from: positions 63-461 of SEQ ID NO:130, positions 1-399 of SEQ ID NO:118, positions 1-399 of SEQ ID NO:122, positions 9-407 of SEQ ID NO:34, positions 1-399 of SEQ ID NO:112, positions 1-399 of SEQ ID NO:114, positions 1-399 of SEQ ID NO:116, or a corresponding sequence from a different HBV strain.

6. The immunotherapeutic composition of any one of Claims 1 to 5, wherein the amino acid sequence of the HBV core antigen is at least 95% identical to an amino acid sequence selected from: positions 462 to 643 of SEQ ID NO:130, positions 400-581 of SEQ ID NO:118, positions 400 to 581 of SEQ ID NO:122, positions 408-589 of SEQ ID NO:34, positions 400-581 of SEQ ID NO:112, positions 400-581 of SEQ ID NO:114, positions 400-581 of SEQ ID NO:116, positions 31-212 of SEQ ID NO:1, positions 31-212 of SEQ ID NO:5, positions 31-212 of SEQ ID NO:9, positions 31-212 of SEQ ID NO:13, positions 31-212 of SEQ ID NO:17, positions 31-212 of SEQ ID NO:21, positions 14-194 of SEQ ID NO:25, positions 31-212 of SEQ ID NO:29, positions 605 to 786 of SEQ ID NO:36, positions 352-533 of SEQ ID NO:38, positions 160-341 of SEQ ID NO:39, positions 605-786 of SEQ ID NO:41, positions 691-872 of SEQ ID NO:92, positions 90-271 of SEQ ID NO:95, positions 2-183 of SEQ ID NO:105, positions 184-395 of SEQ ID NO:105, positions 396-578 of SEQ ID NO:105, positions 579-761 of SEQ ID NO:105, positions 2-183 of SEQ ID NO:106, 338-520 of SEQ ID NO:106, positions 400 to 581 of SEQ ID NO:120, positions 400 to 581 of SEQ ID NO:124, positions 400 to

581 of SEQ ID NO:126, positions 630 to 811 of SEQ ID NO:128, positions 688 to 869 of SEQ ID NO:132, positions 688 to 869 of SEQ ID NO:134, or a corresponding sequence from a different HBV strain.

7. The immunotherapeutic composition of any one of Claims 1 to 6, wherein the amino acid sequence of the HBV core antigen is selected from: positions 462 to 643 of SEQ ID NO:130, positions 400 581 of SEQ ID NO:118, positions 400 to 581 of SEQ ID NO:122, positions 408 589 of SEQ ID NO:34, positions 400 581 of SEQ ID NO:116, positions 400 581 of SEQ ID NO:112, positions 400 581 of SEQ ID NO:114, or a corresponding sequence from a different HBV strain.

8. The immunotherapeutic composition of any one of Claims 1 to 7, wherein the fusion protein comprises an N terminal amino acid sequence of SEQ ID NO:37.

9. The immunotherapeutic composition of any one of Claims 1 to 8, wherein the HBV antigens are arranged in the following order, from N- to C-terminus, in the fusion protein: HBV X antigen, HBV surface antigen, HBV core antigen.

10. The immunotherapeutic composition of any one of Claims 1 to 8, wherein the fusion protein comprises an amino acid sequence that is at least 95% identical to an amino acid sequence selected from SEQ ID NO:130, SEQ ID NO:150 or SEQ ID NO:122.

11. The immunotherapeutic composition of any one of Claims 1 to 8, wherein the fusion protein comprises an amino acid sequence selected from SEQ ID NO:130, SEQ ID NO:150 or SEQ ID NO:122.

12. An immunotherapeutic composition comprising:

a) a yeast vehicle; and

b) a fusion protein comprising HBV antigens, wherein the HBV antigens consist of:

i) an HBV surface antigen having an amino acid sequence that is at least 95% identical to an amino acid sequence of a full-length HBV large surface antigen (L), and;

ii) an HBV core antigen having an amino acid sequence that is at least 95% identical to an amino acid sequence of a full-length HBV core protein;

wherein the composition elicits an HBV-specific immune response.

13. The immunotherapeutic composition of Claim 12, wherein the HBV antigens consist of an amino acid sequence comprising at least 95% of a full-length HBV

large surface antigen (L) fused to the N-terminus of an amino acid sequence comprising at least 95% of a full-length HBV core protein.

14. The immunotherapeutic composition of Claim 12 or Claim 13, wherein the amino acid sequence of the HBV surface antigen is at least 95% identical to an amino acid sequence selected from: positions 1-399 of SEQ ID NO:118, positions 9-407 of SEQ ID NO:34, positions 1-399 of SEQ ID NO:116, positions 1-399 of SEQ ID NO:112, positions 1-399 of SEQ ID NO:114, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:19, SEQ ID NO:23, SEQ ID NO:27, SEQ ID NO:31, positions 90-488 of SEQ ID NO:93, positions 1-399 of SEQ ID NO:120, positions 1-399 of SEQ ID NO:122, positions 1-399 of SEQ ID NO:124, positions 1-399 of SEQ ID NO:126, positions 231-629 of SEQ ID NO:128, positions 63-461 of SEQ ID NO:130, positions 289-687 of SEQ ID NO:132, positions 289-687 of SEQ ID NO:134, or a corresponding sequence from a different HBV strain.

15. The immunotherapeutic composition of any one of Claims 12 to 14, wherein the amino acid sequence of the HBV surface antigen is selected from: positions 1-399 of SEQ ID NO:118, positions 9-407 of SEQ ID NO:34, positions 1-399 of SEQ ID NO:112, positions 1-399 of SEQ ID NO:114, positions 1-399 of SEQ ID NO:116, or a corresponding sequence from a different HBV strain.

16. The immunotherapeutic composition of any one of Claims 12 to 15, wherein the amino acid sequence of the HBV core antigen is at least 95% identical to an amino acid sequence selected from: positions 400-581 of SEQ ID NO:118, positions 408-589 of SEQ ID NO:34, positions 400-581 of SEQ ID NO:116, positions 400-581 of SEQ ID NO:112, positions 400-581 of SEQ ID NO:114, positions 31-212 of SEQ ID NO:1, positions 31-212 of SEQ ID NO:5, positions 31-212 of SEQ ID NO:9, positions 31-212 of SEQ ID NO:13, positions 31-212 of SEQ ID NO:17, positions 31-212 of SEQ ID NO:21, positions 14-194 of SEQ ID NO:25, positions 31-212 of SEQ ID NO:29, positions 605 to 786 of SEQ ID NO:36, positions 352-533 of SEQ ID NO:38, positions 160-341 of SEQ ID NO:39, positions 605-786 of SEQ ID NO:41, positions 691-872 of SEQ ID NO:92, positions 90-271 of SEQ ID NO:95, positions 2-183 of SEQ ID NO:105, positions 184-395 of SEQ ID NO:105, positions 396-578 of SEQ ID NO:105, positions 579-761 of SEQ ID NO:105, positions 2-183 of SEQ ID NO:106, 338-520 of SEQ ID NO:106, positions 400 to 581 of SEQ ID NO:120, positions 400 to 581 of SEQ ID NO:122, positions 400 to 581 of SEQ ID NO:124, positions 400 to 581 of SEQ ID NO:126, positions 630 to 811 of SEQ ID NO:128, positions 462 to 643 of SEQ ID NO:130, positions 688 to 869 of SEQ

ID NO:132, positions 688 to 869 of SEQ ID NO:134, or a corresponding sequence from a different HBV strain.

17. The immunotherapeutic composition of any one of Claims 12 to 15, wherein the amino acid sequence of the HBV core antigen is selected from: positions 400-581 of SEQ ID NO:118, positions 408-589 of SEQ ID NO:34, positions 400-581 of SEQ ID NO:116, positions 400-581 of SEQ ID NO:112, positions 400-581 of SEQ ID NO:114, or a corresponding sequence from a different HBV strain.

18. The immunotherapeutic composition of any one of Claims 12 to 17, wherein the HBV antigens consist of an amino acid sequence that is at least 95% identical to an amino acid sequence selected from: SEQ ID NO:118, SEQ ID NO:116, positions 9-589 of SEQ ID NO:34, SEQ ID NO:112, SEQ ID NO:114, or a corresponding sequence for a different HBV strain.

19. The composition of any one of Claims 12 to 18, wherein the fusion protein comprises an N-terminal amino acid sequence of SEQ ID NO:37.

20. The immunotherapeutic composition of any one of Claims 12 to 18, wherein the fusion protein comprises an amino acid sequence of SEQ ID NO:151 or SEQ ID NO:34.

21. An immunotherapeutic composition comprising:

a) a yeast vehicle; and

b) a fusion protein comprising HBV antigens, wherein the HBV antigens consist of:

i) an HBV surface antigen consisting of at least one immunogenic domain of full-length HBV large (L), medium (M) or small (S) surface antigen;

ii) an HBV polymerase antigen consisting of at least one immunogenic domain of full-length HBV polymerase or of the reverse transcriptase (RT) domain of HBV polymerase;

iii) an HBV core antigen consisting of at least one immunogenic domain of full-length HBV core protein or of full-length HBV e-antigen; and

iv) an HBV X antigen consisting of at least one immunogenic domain of full-length HBV X antigen;

wherein the composition elicits an HBV-specific immune response.

22. The immunotherapeutic composition of Claim 21, wherein the HBV antigens consist of the amino acid sequence that is at least 95% identical to an amino acid sequence selected from: SEQ ID NO: 134, SEQ ID NO:132, positions 6 to 939 of SEQ ID NO:36, positions 92 to 1025 of SEQ ID NO:92, positions 90 to 778 of SEQ ID NO:101, positions 7 to 694 of SEQ ID NO:102, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:124, SEQ ID NO:126, or a corresponding sequence from a different HBV strain.

23. An immunotherapeutic composition comprising:

a) a yeast vehicle; and

b) a fusion protein comprising HBV antigens, wherein the HBV antigens consist of:

i) an HBV surface antigen consisting of at least one immunogenic domain of hepatocyte receptor region of Pre-S1 of the HBV large surface antigen (L) and at least one immunogenic domain of HBV small surface antigen (S);

ii) an HBV polymerase antigen consisting of at least one immunogenic domain of reverse transcriptase domain of HBV polymerase; and

iii) an HBV core antigen consisting of at least one immunogenic domain of HBV core protein.

wherein the composition elicits an HBV-specific immune response.

24. The immunotherapeutic composition of Claim 23, wherein the HBV antigens consist of an amino acid sequence that is at least 95% identical to an amino acid sequence selected from: SEQ ID NO:128, SEQ ID NO:120, positions 6-786 of SEQ ID NO:41, or a corresponding sequence from a different HBV strain.

25. An immunotherapeutic composition comprising:

a) a yeast vehicle; and

b) a fusion protein comprising HBV antigens, wherein the HBV antigens consist of:

i) an HBV polymerase antigen consisting of at least one immunogenic domain of the reverse transcriptase (RT) domain of HBV polymerase; and

ii) an HBV core antigen consisting of at least one immunogenic domain of HBV core protein;

wherein the composition elicits an HBV-specific immune response.

26. The immunotherapeutic composition of Claim 25, wherein the fusion protein has an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:38 or a corresponding sequence from a different HBV strain.

27. An immunotherapeutic composition comprising:

a) a yeast vehicle; and

b) a fusion protein comprising HBV antigens, wherein the HBV antigens consist of:

i) an HBV X antigen consisting of at least one immunogenic domain of HBV X antigen; and

ii) an HBV core antigen consisting of at least one immunogenic domain of HBV core protein;

wherein the composition elicits an HBV-specific immune response.

28. The immunotherapeutic composition of Claim 27, wherein the fusion protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO:39 or a corresponding sequence from a different HBV strain.

29. An immunotherapeutic composition comprising:

a) a yeast vehicle; and

b) a fusion protein comprising an HBV antigen selected from the group consisting of:

i) HBV surface antigen consisting of at least one immunogenic domain of an HBV large surface antigen (L);

ii) an HBV polymerase antigen consisting of at least one immunogenic domain of a reverse transcriptase domain of HBV polymerase;

iii) an HBV core antigen consisting of at least one immunogenic domain of an HBV core protein; and

iv) an HBV X antigen consisting of at least one immunogenic domain of a full-length HBV X antigen;

wherein the composition elicits an HBV-specific immune response.

30. The immunotherapeutic composition of Claim 29, wherein the fusion protein comprises an amino acid sequence that is at least 95% identical to the amino acid sequence of: SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:40, SEQ ID NO:95, SEQ ID NO:96, or a corresponding sequence from a different HBV strain.

31. The immunotherapeutic composition of Claim 29, comprising any two, three or four of the immunotherapeutic compositions of (i), (ii), (iii) or (iv).

32. An immunotherapeutic composition comprising:

a) a yeast vehicle; and

b) a fusion protein comprising HBV antigens, wherein the HBV antigens consist of at least one immunogenic domain of two, three or four HBV antigens selected from HBV surface antigens, HBV polymerase antigens, HBV core antigens or HBV X antigens, wherein each of the HBV antigens is from a different HBV genotype;

wherein the composition elicits an HBV-specific immune response.

33. The immunotherapeutic composition of Claim 32, wherein the HBV antigens consist of four HBV core antigens, and wherein the fusion protein has an amino acid sequence that is at least 95% identical to SEQ ID NO:105, or a corresponding sequence from a different HBV strain.

34. An immunotherapeutic composition comprising:

a) a yeast vehicle; and

b) a fusion protein comprising at least two HBV core proteins and at least two HBV X antigens, where each of the HBV core proteins is from a different HBV genotype and where each of the HBV X antigens is from a different HBV genotype;

wherein the composition elicits an HBV-specific immune response.

35. The immunotherapeutic composition of Claim 34, wherein the fusion protein has an amino acid sequence that is at least 95% identical to SEQ ID NO:106, or a corresponding sequence from a different HBV strain.

36. The immunotherapeutic composition of any one of Claims 1 to 35, wherein the fusion protein is expressed by the yeast vehicle.

37. The immunotherapeutic composition of any one of Claims 1 to 36, wherein the yeast vehicle is a whole yeast.

38. The immunotherapeutic composition of Claim 37, wherein the whole yeast is killed.

39. The immunotherapeutic composition of Claim 37, wherein the whole yeast is heat-inactivated.

40. The immunotherapeutic composition of any one of Claims 1 to 39, wherein the yeast vehicle is from *Saccharomyces cerevisiae*.

41. The immunotherapeutic composition of any one of Claims 1 to 40, wherein the composition contains greater than 90% yeast protein and is formulated for administration by injection of a patient.

42. An immunotherapeutic composition comprising:

a) a whole, heat inactivated yeast from *Saccharomyces cerevisiae*; and

b) an HBV fusion protein expressed by the yeast, wherein the fusion protein comprises SEQ ID NO:130.

43. An immunotherapeutic composition comprising:

a) a whole, heat-inactivated yeast from *Saccharomyces cerevisiae*; and

b) an HBV fusion protein expressed by the yeast, wherein the fusion protein comprises SEQ ID NO:150.

44. An immunotherapeutic composition comprising:

a) a whole, heat-inactivated yeast from *Saccharomyces cerevisiae*; and

b) an HBV fusion protein expressed by the yeast, wherein the fusion protein comprises SEQ ID NO:118.

45. An immunotherapeutic composition comprising:

a) a whole, heat-inactivated yeast from *Saccharomyces cerevisiae*; and

b) an HBV fusion protein expressed by the yeast, wherein the fusion protein comprises SEQ ID NO:151.

46. An immunotherapeutic composition comprising:

a) a whole, heat-inactivated yeast from *Saccharomyces cerevisiae*; and

b) an HBV fusion protein expressed by the yeast, wherein the fusion protein comprises the amino acid sequence of SEQ ID NO:34.

47. A fusion protein comprising HBV antigens, wherein the fusion protein comprises an amino acid sequence that is at least 95% identical to an amino acid sequence of: SEQ ID NO:130, SEQ ID NO:150, SEQ ID NO:118, SEQ ID NO:151, SEQ ID NO:34, SEQ ID NO:120, SEQ ID NO:122, SEQ ID NO:124, SEQ ID NO:126, SEQ ID NO:128, SEQ ID NO:132, SEQ ID NO:134, SEQ ID NO:112, SEQ ID NO:114, SEQ ID NO:116, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, SEQ ID NO:98, SEQ ID NO:99, SEQ ID NO:100, SEQ ID NO:101, SEQ ID NO:102, SEQ ID NO:105, SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, and SEQ ID NO:110.

48. A recombinant nucleic acid molecule encoding the fusion protein of Claim 47.

49. The recombinant nucleic acid molecule of Claim 48, wherein the recombinant nucleic acid molecule comprises a nucleic acid sequence selected from: SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:91, SEQ ID NO:111, SEQ ID NO:113, SEQ ID NO:115, SEQ ID NO:117, SEQ ID NO:119, SEQ ID NO:121, SEQ ID NO:123, SEQ ID NO:125, SEQ ID NO:127, SEQ ID NO:129, SEQ ID NO:131, or SEQ ID NO:133.

50. An isolated cell transfected with the recombinant nucleic acid molecule of Claim 48 or Claim 49.

51. The isolated cell of Claim 50, wherein the cell is a yeast cell.

52. A composition comprising the fusion protein of Claim 47.

53. A composition comprising the recombinant nucleic acid molecule of Claim 48 or Claim 49.

54. A composition comprising the isolated cell of Claim 50 or Claim 51.

55. A method to treat hepatitis B virus (HBV) infection or at least one symptom resulting from HBV infection in a subject, comprising administering to a subject that has been infected with HBV at least one composition according to any one of Claims 1 to 46 or 52 to 54, wherein administration of the composition to the subject reduces HBV infection or at least one symptom resulting from HBV infection in a subject.

56. The method of Claim 55, wherein administration of the composition to the subject results in seroconversion in the subject.

57. The method of Claim 55, wherein administration of the composition to the subject reduces HBV viral load in the subject.

58. The method of Claim 55, wherein administration of the composition to the subject reduces liver damage in the subject.

59. The method of Claim 55, further comprising administering to the subject one or more additional compounds useful for treating or ameliorating a symptom of HBV infection.

60. The method of Claim 59, wherein the compound is an anti-viral compound.

61. The method of Claim 60, wherein the anti-viral compound is a nucleotide analogue reverse transcriptase inhibitor.

62. The method of Claim 60, wherein the anti-viral compound is selected from the group consisting of: tenofovir, lamivudine, adefovir, telbivudine, entecavir, and combinations thereof.

63. The method of Claim 60, wherein the anti-viral compound is tenofovir.

64. The method of Claim 59, wherein the compound is an interferon.

65. A method to elicit an antigen-specific, cell-mediated immune response against an HBV antigen, comprising administering to a subject at least one composition according to any one of Claims 1 to 46 or 52 to 54.

66. A method to prevent HBV infection in a subject, comprising administering to a subject that has not been infected with HBV, at least one composition according to any one of Claims 1 to 46 or 52 to 54.

67. A method to immunize a population of individuals against HBV, comprising administering to the population of individuals at least one composition according to any one of Claims 1 to 46 or 52 to 54.

68. The method of any one of Claims 55 to 67, wherein the method comprises administering at least two compositions according to any one of Claims 1 to 46 or 52 to 54.

69. The method of Claim 68, wherein the compositions are administered concurrently to an individual.

70. The method of Claim 68, wherein the compositions are administered sequentially to an individual.

71. The method of Claim 68, wherein each of the compositions is administered by injection to a different site on the individual.

72. The composition of any one of Claims 1 to 46 or 52 to 54, for use to treat HBV infection or a symptom thereof.

73. The composition of any one of Claims 1 to 46 or 52 to 54, for use to prevent HBV infection or a symptom thereof.

74. Use of the composition of any one of Claims 1 to 46 or 52 to 54 in the preparation of a medicament to treat HBV infection.

75. Use of the composition of any one of Claims 1 to 46 or 52 to 54 in the preparation of a medicament to prevent HBV infection.

What is claimed is:

1. An immunotherapeutic composition comprising:

a) a yeast vehicle; and

b) a fusion protein comprising HBV antigens, wherein the HBV antigens consist of:

i) an HBV X antigen having an amino acid sequence that is at least 90% identical to positions 1-60 of SEQ ID NO:130;

ii) an HBV surface antigen having an amino acid sequence that is at least 90% identical to positions 63-461 of SEQ ID NO:130; and

iii) an HBV core antigen having an amino acid sequence that is at least 90% identical to positions 462 to 643 of SEQ ID NO:130; wherein the composition elicits an HBV-specific immune response and wherein the fusion protein is expressed by the yeast vehicle.

2. The immunotherapeutic composition of claim 1, wherein the HBV antigens are arranged in the following order, from N- to C-terminus, in the fusion protein: HBV X antigen, HBV surface antigen, HBV core antigen.

3. The immunotherapeutic composition of claim 1, wherein the HBV antigens consist of an amino acid sequence that is at least 90% identical to SEQ ID NO:130.

4. The immunotherapeutic composition of claim 1, wherein the fusion protein comprises an amino acid sequence of SEQ ID NO:130.

5. The immunotherapeutic composition of claim 1, wherein the fusion protein comprises an amino acid sequence of SEQ ID NO:150.

6. The immunotherapeutic composition of claim 1, wherein the fusion protein consists of an amino acid sequence of SEQ ID NO:150.

7. The immunotherapeutic composition of claim 1, wherein the amino acid sequence of HBV X antigen consists of positions 1-60 of SEQ ID NO:130.

8. The immunotherapeutic composition of claim 1, wherein the amino acid sequence of the HBV surface antigen consists of positions 63-461 of SEQ ID NO:130.

9. The immunotherapeutic composition of claim 1, wherein the amino acid sequence of the HBV core antigen consists of positions 462 to 643 of SEQ ID NO:130.

10. The immunotherapeutic composition of claim 1, wherein the yeast vehicle is from Saccharomyces cerevisiae.

11. The immunotherapeutic composition of claim 1, wherein the yeast vehicle is a whole yeast.

12. The immunotherapeutic composition of claim 11, wherein the whole yeast is heat-inactivated.

13. The immunotherapeutic composition of claim 11, wherein the whole yeast is killed.

14. The immunotherapeutic composition of claim 12, wherein the whole yeast has been lyophilized.

15. The immunotherapeutic composition of claim 11, wherein the yeast vehicle is from Saccharomyces cerevisiae.

16. The immunotherapeutic composition of claim 1, comprising a pharmaceutically acceptable excipient.

17. A yeast expressing a fusion protein comprising HBV antigens, wherein the HBV antigens consist of:

a) an HBV X antigen having an amino acid sequence that is at least 90% identical to positions 1-60 of SEQ ID NO:130;

b) an HBV surface antigen having an amino acid sequence that is at least 90% identical to positions 63-461 of SEQ ID NO:130; and c) an HBV core antigen having an amino acid sequence that is at least 90% identical to positions 462 to 643 of SEQ ID NO:130.

18. The yeast of claim 17, wherein the amino acid sequence of HBV X antigen consists of positions 1-60 of SEQ ID NO:130.

19. The yeast of claim 17, wherein the amino acid sequence of the HBV surface antigen consists of positions 63-461 of SEQ ID NO:130.

20. The yeast of claim 17, wherein the amino acid sequence of the HBV core antigen consists of positions 462 to 643 of SEQ ID NO:130.

21. The yeast of claim 17, wherein the HBV antigens consist of an amino acid sequence that is at least 90% identical to SEQ ID NO:130.

22. The yeast of claim 17, wherein the fusion protein consists of an amino acid sequence of SEQ ID NO:150.

23. The yeast of claim 17, wherein the yeast is from Saccharomyces cerevisiae.

24. A fusion protein comprising HBV antigens, wherein the fusion protein comprises an amino acid sequence that is at least 90% identical to an amino acid sequence of SEQ ID NO:130 or SEQ ID NO:150.

25. The fusion protein of claim 24, wherein the fusion protein comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:130.

26. The fusion protein of claim 24, wherein the fusion protein comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:150.

27. The fusion protein of claim 24, wherein the fusion protein consists of an amino acid sequence of SEQ ID NO:150.